Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -50.93% is 46% above its 5-year average of -93.66%, near the high end of its 5-year range (-237.68%–-34.56%).
As of the fiscal period ended Tuesday, June 30, 2026. 57.17% above its 12-month average of -118.92%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -50.93%.
RETURN ON EQUITY (ROE)
-50.93%
RETURN ON EQUITY (ROE) AVG TTM
-118.92%
RETURN ON EQUITY (ROE) AVG 3Y
-111.06%
RETURN ON EQUITY (ROE) AVG 5Y
-93.66%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+57.17%
CURRENT VS 3Y AVG
+54.14%
CURRENT VS 5Y AVG
+45.62%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.55%
median of 586 covered companies
CURRENT VS SECTOR MEDIAN
-28.79%
vs the sector median at left
Damora Therapeutics, Inc.
Market Cap
$1.17B
Return on Equity (ROE)
-50.93%
TTM Avg
-118.92%
3Y Avg
-111.06%
5Y Avg
-93.66%
Market Cap
$1.14B
Return on Equity (ROE)
-6.16%
TTM Avg
-10.85%
3Y Avg
-14.08%
5Y Avg
-9.38%
Market Cap
$1.15B
Return on Equity (ROE)
2.51%
TTM Avg
3.60%
3Y Avg
0.50%
5Y Avg
-7.05%
Market Cap
$1.13B
Return on Equity (ROE)
-244.91%
TTM Avg
-17.45%
3Y Avg
-30.16%
5Y Avg
-48.76%
Market Cap
$1.13B
Return on Equity (ROE)
10.23%
TTM Avg
17.11%
3Y Avg
18.25%
5Y Avg
14.55%
Market Cap
$1.16B
Return on Equity (ROE)
N/A
TTM Avg
35.70%
3Y Avg
35.70%
5Y Avg
35.70%
Market Cap
$1.17B
Return on Equity (ROE)
-17.40%
TTM Avg
-189.25%
3Y Avg
-172.42%
5Y Avg
-134.67%
Market Cap
$1.11B
Return on Equity (ROE)
-39.54%
TTM Avg
-24.09%
3Y Avg
36.77%
5Y Avg
36.77%
Market Cap
$1.09B
Return on Equity (ROE)
22.66%
TTM Avg
22.95%
3Y Avg
21.85%
5Y Avg
17.09%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.17B | -50.93% | -118.92% | -111.06% | -93.66% |
| OPKO Health, Inc. (OPK)vs › | $1.14B | -6.16% | -10.85% | -14.08% | -9.38% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 2.51% | 3.60% | 0.50% | -7.05% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | -244.91% | -17.45% | -30.16% | -48.76% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 10.23% | 17.11% | 18.25% | 14.55% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.16B | N/A | 35.70% | 35.70% | 35.70% |
| Nektar Therapeutics (NKTR)vs › | $1.17B | -17.40% | -189.25% | -172.42% | -134.67% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.11B | -39.54% | -24.09% | 36.77% | 36.77% |
| IRadimed Corporation (IRMD)vs › | $1.09B | 22.66% | 22.95% | 21.85% | 17.09% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.08B | -63.62% | -41.08% | -23.78% | -22.76% |
ROE
-50.9%
ROA
-48.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -50.93% |
| 2026-03-31 | -46.07% |
| 2025-12-31 | -87.29% |
| 2025-09-30 | -237.68% |
| 2025-06-30 | -172.64% |
| 2025-03-31 | -149.77% |
| 2024-12-31 | -148.15% |
| 2024-09-30 | -101.14% |
| 2024-06-30 | -107.79% |
| 2024-03-31 | -109.49% |
| 2023-12-31 | -118.61% |
| 2023-09-30 | -122.90% |
| 2023-06-30 | -117.93% |
| 2023-03-31 | -114.60% |
| 2022-12-31 | -99.79% |
| 2022-09-30 | -83.83% |
| 2022-06-30 | -70.45% |
| 2022-03-31 | -54.63% |
| 2021-12-31 | -44.15% |
| 2021-09-30 | -38.51% |
| 2021-06-30 | -34.56% |
